At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 932 enrolled
Drug / intervention
GLPG1972 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of 3 Doses of S201086/GLPG1972 Administered Orally Once Daily in Patients With Knee Osteoarthritis. A 52-week International, Multi-regional, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
In Brief
A Phase 2 clinical trial evaluating GLPG1972 and Placebo for Osteoarthritis. Completed, enrolled 932 participants across 44 sites.
Detailed Summary
This study is a phase 2, 52-week international, multi-regional, multi-center, randomized, double-blind, placebo-controlled dose-ranging study for the treatment of osteoarthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesUnited States
CollaboratorsInstitut de Recherches Internationales Servier
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartAug 2018
Primary CompletionJul 2020
TodayJul 2026
First PostedJul 23, 2018
Enrollment StartAug 14, 2018
Primary CompletionJul 14, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.9 years ago
Interventions
GLPG1972drug
Film-coated tablets of GLPG1972 for oral use.
Placebodrug
Film-coated tablets of matching placebo for oral use.